Investigation alert: Aldeyra, Eagle Pharmaceuticals and

SAN DIEGO, June 13, 2024 (GLOBE NEWSWIRE) — Shareholder rights law firm Johnson Fistel, LLP is investigating possible violations of federal and state laws by certain officers of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) and Blue Ridge Bankshares, Inc. (NYSE: BRBS).

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX)

Johnson Fistel, LLP is investigating on behalf of Aldeyra Therapeutics, Inc. potential claims against certain of its officers and directors.

If you are a current, long-term If you are an Aldeyra shareholder and hold shares before March 17, 2022, you may have the right to indemnify Aldeyra for the alleged harm caused by the Company’s officers and directors by holding them personally liable. You may also be able to help reform the Company’s corporate governance to prevent future wrongdoing. You can click on the link below or copy and paste it into a browser to participate in this action:

A class action lawsuit was recently filed against the Company. The lawsuit alleges that Aldeyra made materially false and/or misleading statements and/or failed to disclose material adverse facts about the Company’s business, operations and compliance policies, including: (i) the New Drug Application for ADX-2191 (“NDA”) did not contain adequate and well-controlled studies and therefore failed to provide substantial evidence of the efficacy of ADX-2191; (ii) as a result, the FDA was unlikely to approve the NDA for ADX-2191 in its current form; and (iii) accordingly, the Company had overstated the clinical and/or commercial prospects of ADX-2191.

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)

Johnson Fistel, LLP is investigating on behalf of Eagle Pharmaceuticals, Inc. potential claims against certain of its officers and directors.

If you are a current, long-term shareholder as of August 8, 2023 and have held your shares continuously since April 21, 2022, you may be able to indemnify the Company for the alleged harm caused by the Company’s officers and directors by holding them personally liable. You may also be able to help reform the Company’s corporate governance to prevent future wrongdoing. You can click or copy and paste the link below into a browser to participate in this action:

A class action lawsuit was recently filed against the company. The class action lawsuit alleges that the defendants made false statements and failed to disclose that (i) Eagle Pharmaceuticals experienced slower-than-expected throughput from a wholesale customer, primarily due to inventory shortages; (ii) Eagle Pharmaceuticals overstated its sales as a result; and (iii) Eagle Pharmaceuticals did not have effective internal controls and procedures for financial reporting of sales of its lung cancer drug PEMFEXY.

Blue Ridge Bankshares, Inc. (NYSE: BRBS)

Johnson Fistel, LLP is investigating on behalf of Blue Ridge Bankshares, Inc. potential claims against certain of its officers and directors.

If you are a current, long-term shareholder of Blue Ridge Bankshares and hold shares before March 10, 2023, you can click or copy and paste the following link into a browser to participate in this promotion:

A class action lawsuit was recently filed against Blue Ridge Bankshares. According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Blue Ridge Bankshares, Inc.’s financial statements from March 10, 2023 to present contained certain errors; (2) Blue Ridge Bankshares would be required to re-file its previously filed financial statements from March 10, 2023 to October 31, 2023 as a result; and (3) as a result, defendants’ statements about their business, operations, and prospects were materially false and misleading and/or did not have a reasonable basis at any time. When the true details became available to the market, the lawsuit alleges that investors suffered damages.

About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder class action lawsuits involving derivatives and securities. Johnson Fistel seeks to recover losses resulting from violations of the federal securities laws. For more information about the firm and its attorneys, visit http://www.johnsonfistel.com. Attorney advertising. Past results are no guarantee of future results.

Lawyer advertising.
Past results are no guarantee of future results.
Services can be provided by attorneys in any of our offices.

Johnson Fistel, LLP has paid for the distribution of this advertisement and Frank J. Johnson is the attorney responsible for its content.

Contact:
Johnson Fistula, LLP
501 W. Broadway, Suite 800, San Diego, CA 92101
James Baker, Investor Relations or Frank J. Johnson, Esq., (619) 814-4471
[email protected] or [email protected]